Haemonetics Corporation (HAE)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$1.02 (+1.23%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Haemonetics Corporation (HAE)
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Key Insights

Critical company metrics and information
  • Share Price

    $83.55
  • Market Cap

    $4.20 Billion
  • Total Outstanding Shares

    50.22 Million Shares
  • Total Employees

    3,657
  • Dividend

    No dividend
  • IPO Date

    May 9, 1991
  • SIC Description

    Surgical & Medical Instruments & Apparatus
  • Homepage

    https://www.haemonetics.com

Historical Stock Splits

If you bought 1 share of HAE before December 3, 2012, you'd have 2 shares today.
Execution DateSplit Amount
December 3, 20122-for-1

Cash Flow Statement

September 29, 2023 to September 28, 2024
MetricValue
Net Cash Flow, Continuing$-54.80 Million
Net Cash Flow From Operating Activities$84.94 Million
Exchange Gains/Losses$3.08 Million
Net Cash Flow From Financing Activities$304.81 Million
Net Cash Flow From Investing Activities$-444.56 Million
Net Cash Flow From Investing Activities, Continuing$-444.56 Million
Net Cash Flow$-51.72 Million
Net Cash Flow From Financing Activities, Continuing$304.81 Million
Net Cash Flow From Operating Activities, Continuing$84.94 Million

Income Statement

September 29, 2023 to September 28, 2024
MetricValue
Diluted Earnings Per Share$2.41
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Diluted Average Shares$102.85 Million
Depreciation and Amortization$109.52 Million
Operating Income/Loss$167.37 Million
Net Income/Loss Available To Common Stockholders, Basic$123.81 Million
Revenues$1.36 Billion
Net Income/Loss Attributable To Parent$123.81 Million
Income/Loss From Continuing Operations Before Tax$158.86 Million
Basic Earnings Per Share$2.44
Cost Of Revenue$645.09 Million
Basic Average Shares$101.72 Million
Income/Loss From Continuing Operations After Tax$123.81 Million
Gross Profit$716.13 Million
Research and Development$60.10 Million
Net Income/Loss$123.81 Million
Selling, General, and Administrative Expenses$448.59 Million
Operating Expenses$548.76 Million
Benefits Costs and Expenses$1.20 Billion
Income Tax Expense/Benefit, Deferred$-15.16 Million
Preferred Stock Dividends And Other Adjustments$0.00
Income Tax Expense/Benefit$35.05 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Costs And Expenses$1.20 Billion

Balance Sheet

September 29, 2023 to September 28, 2024
MetricValue
Intangible Assets$487.84 Million
Inventory$382.11 Million
Wages$49.30 Million
Liabilities And Equity$2.53 Billion
Assets$2.53 Billion
Current Assets$955.90 Million
Noncurrent Liabilities$1.37 Billion
Liabilities$1.65 Billion
Noncurrent Assets$1.57 Billion
Equity Attributable To Noncontrolling Interest$0.00
Current Liabilities$273.95 Million
Other Non-current Assets$781.01 Million
Fixed Assets$300.48 Million
Equity$878.85 Million
Equity Attributable To Parent$878.85 Million
Other Current Liabilities$155.40 Million
Accounts Payable$69.24 Million
Other Current Assets$573.80 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Related Companies

View additional S&P 500 companies similar to Haemonetics Corporation (HAE)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.